Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer | MicrobiomeTrials← Back to trialsNCT05113537
Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2022-07-08Est. Completion: 2027-05-31
Enrollment target: 30 participants Locations- University of California, San Francisco, San Francisco, California, United States
Other microbiome trials you might be interested in
Head and Neck CancerHead and Neck Squamous Cell CarcinomaParanasal Sinus NeoplasmsNasopharyngeal CarcinomaOropharyngeal Squamous Cell CarcinomaHypopharyngeal CancerCarcinoma of LarynxOral Squamous Cell CarcinomaSalivary Gland CancerAdenoid Cystic CarcinomaProstate CancerMetastatic Castration Resistant Prostate Cancer
Background:
Head and neck cancers (HNCs) account for about 5% of all cancers worldwide. They grow in the mouth, throat,…
Bethesda, United StatesEst. completion Oct 1, 2036
Metastatic Castration-Resistant Prostate Carcinoma
This study is being performed to establish the association between absorbed dose to tumor and response and absorbed dose…
Ann Arbor, United StatesEst. completion Jan 23, 2031
Prostate Cancer
The purpose of this study is to determine whether \[225Ac\]Ac-PSMA-617 (AAA817), given for up to 6 cycles at a dose of 1…
Homewood, United StatesEst. completion Sep 29, 2028